Bioactivity:

Varespladib, a specific and effective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor(IC50=7 nM), has been investigated for the treatment and prevention of sickle cell disease, vaso-occlusive crisis, and acute coronary syndrome.

CAS nr:

172732-68-2

Purity:

98%

Molecular Weight:

380,39

SMILES:

CCc1c(C(=O)C(=O)N)c2c(cccc2OCC(=O)O)n1Cc1ccccc1

Formula:

C21H20N2O5

Pathway:

Metabolism

Target:

Phospholipase